Urine

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Friday, March 1, 2024
Urination, Diabetes, Fever, Woman, Anemia, Penis, Workplace, Kidney, Blood, Smoking, Mineral, Hormone, Pain, Weight loss, Infection, Rib, Nausea, Vomiting, Human, Kidney cancer, University, Somatic symptom disorder, AUA, Tobacco, Disease, Urine, Risk factor, Low back pain, Risk, American Urological Association, Salt, Water, Phosphorus

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

Alen Air Purifiers are Transforming Home Health to Fight Rising Indoor Air Quality Dangers

Retrieved on: 
Thursday, March 7, 2024
Residential Building & Real Estate, Consumer Electronics, Technology, Construction & Property, Health, General Health, Specialty, Retail, Family, Home Goods, Consumer, Pet, Air pollution, Soot, Atmosphere, Alen, Dander, Ammonia, Respiratory system, Volatile organic compound, DVM, Natural gas, Carbon monoxide, Dizziness, Asthma, Harvard University, NO2, HEPA, Allergy, Risk, Atmosphere of Earth, Saliva, Benzene, Cleaning, Nitrogen dioxide, Death, Spore, Headache, EPA, Allergen, Urine, Organic compound, Ventilation, Pollen, AAFA, Human, Methane

The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.

Key Points: 
  • The company’s education campaign focuses on pervasive health risks associated with poor indoor air quality.
  • “The dangers of poor indoor air quality are not just invisible – they silently jeopardize our health, amplifying the risk of respiratory issues, allergies and long-term health complications,” said Alen CEO, Warburg Lee.
  • Alen air purifiers with HEPA fresh filtration capture fine particles, including ash, soot and VOCs, effectively removing them from the indoor air and reducing exposure to harmful pollutants and allergens like pollen, pet dander, and mold spores, providing symptom relief and improving overall indoor air quality.
  • Addressing these sources of indoor air pollution typically involves implementing strategies such as improving ventilation, using air purifiers with HEPA filters like Alen, and reducing or eliminating the use of products with harmful chemicals.

Drug Abuse Testing Market, Size, Global Forecast Report 2024-2030: Focus on Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, and LSD - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Medical Devices, Hemp, Cannabis, Health Technology, Other Health, General Health, Pharmaceutical, Health, Agriculture, Natural Resources, Collection, Molina Healthcare, Breathalyzer, Urine, Cocaine, Education, Prohibition, Substance abuse, Health Promotion International, Abuse, Government, Sport, Urinalysis, Saliva, Illegal drug trade, Organization, Psychological abuse, Drug overdose, CDC, Mortality, Ageing, Laboratory, Research, Drug

Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.

Key Points: 
  • Drug of Abuse Testing Market size is expected to hit US$ 10.28 Billion by 2030 from US$ 6.18 Billion in 2023.
  • Innovations in technology are continuously emerging to expedite and enhance drug testing efficiency in response to the growing demand for such services.
  • The drug abuse testing market is generally pushed by strict laws that mandate drug abuse testing, growing government initiatives concerning drug abuse, rising consumption of alcohol and different drugs, and growing mortality because of drugs.
  • The growing global population engaged in alcohol and illicit drug use, encompassing substances like marijuana and cocaine, drives the drug abuse testing market's growth.

Toyoda Gosei Invests in Craif, Inc., a Startup Developing Urine Test Kits for Higher Possibility of the Early Detection of Cancer

Retrieved on: 
Tuesday, March 5, 2024
Professional Services, Oncology, Start-Up, General Automotive, Aftermarket, Medical Devices, Automotive, Biotechnology, Automotive Manufacturing, Medical Supplies, Manufacturing, Health, Nagoya University, Multimedia, AI, Molina Healthcare, Investment, MicroRNA, Gosei, Urine, Longevity, Cancer

Toyoda Gosei Co., Ltd. (TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University that develops urine test kits that enhance the possibility of the early detection of cancer.

Key Points: 
  • Toyoda Gosei Co., Ltd. (TOKYO:7282), in its efforts to pioneer new businesses to resolve societal healthcare issues, has invested1 in Craif, Inc., a startup out of Nagoya University that develops urine test kits that enhance the possibility of the early detection of cancer.
  • These kits comprehensively and efficiently capture and measure small microRNA molecules called miRNA2 in urine, which are generally difficult to detect.
  • 1 Investment made in February 2024, through Toyoda Gosei’s Corporate Venture Capital Dept., an internal organization dedicated to these investments.
  • 2 The amount and type of miRNA contained in urine differs depending on the type of cancer and its progression.

JARDIANCE Market Size, Forecast, and Emerging Insights, 2019-2023 and 2024-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024
Health, Pharmaceutical, Heart, AMI, EMPOWER, SWOT, EU4, Empagliflozin, Risk, Myocardial infarction, Safety, Acute kidney injury, Patient, SGLT2, Urine, Kidney, Glucose, Kidney disease, Mortality, Research, Pharmaceutical industry

Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the JARDIANCE market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.
  • JARDIANCE (Empagliflozin) is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney.
  • The report also highlights the JARDIANCE research and development activities in myocardial infarction across the United States, Europe and Japan.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of JARDIANCE in myocardial infarction.

Epicore Biosystems and the U.S. Anti-Doping Agency Partner on an Innovative Collaboration to Deploy Sweat-Sensing Biowearables for Doping Control

Retrieved on: 
Tuesday, February 27, 2024
Skin, Sport, Safety, Biomarker, Biomedical Research, Perspiration, Organization, Urine, USADA, Athlete, Stagnation, Partnership, Management

CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore'), a digital health solutions company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, and the U.S. Anti-Doping Agency (USADA) have partnered to bring Epicore's novel biosensing capabilities to the anti-doping world as a new drug detection method to complement existing urine and blood collections.

Key Points: 
  • The collaboration aims to do just that.
  • To date, athletes have been required to submit blood and/or urine samples for anti-doping efforts, which can be time-consuming and feel invasive for athletes.
  • The Epicore and USADA partnership aims to dramatically improve the status quo by providing a non-invasive, wearable approach to conventional screening using biomarkers and drug detection in sweat.
  • The technology could be especially valuable for in-competition testing to minimize the impact of doping control during a time when athletes face significant demands on their time and bodies.

Healthy.io Expands Leadership Team, Appoints Becca LaFond as U.S. General Manager

Retrieved on: 
Tuesday, February 27, 2024
Olive, Kidney disease, Acquisition, Diabetes, Healthy.io, ACR, Conditional sentence, FDA, Dialysis, Growth, Risk, CKD, Patient, Policy, Urine, Public, Pharmaceutical industry

BOSTON, Feb. 27, 2024 /PRNewswire/ -- Healthy.io, the developer of the first and only FDA-cleared smartphone-powered at-home kidney test, today announced the appointment of Becca LaFond as the company's new U.S. General Manager.

Key Points: 
  • LaFond will work closely with Healthy.io partners to scale the commercialization of its Minuteful Kidney service while enhancing execution across payers, systems, and pharmaceutical companies.
  • LaFond brings over two decades of experience in the healthcare industry and expertise in optimizing operations through technology for better outcomes.
  • The addition of LaFond to Healthy.io's executive suite marks a continued expansion of its leadership team.
  • "We're excited to have Becca join the team to drive our next phase of expansion," said Healthy.io CEO Geoff Martin.

Mountain View Medical Laboratory Announces Rebranding to Gnosis

Retrieved on: 
Monday, February 26, 2024
Medical laboratory, Toxicology, COVID-19 testing, ABB, COVID-19, Genetics, Pathology, Health, Patient, Urine, Laboratory, Insurance, Public, Pharmaceutical industry

HEMET, Calif. , Feb. 26, 2024 /PRNewswire/ -- Mountain View Medical Laboratory, a leading and established lab backed by a decade of experience in providing a comprehensive range of testing solutions, today announced a complete rebranding to become "Gnosis."

Key Points: 
  • HEMET, Calif. , Feb. 26, 2024 /PRNewswire/ -- Mountain View Medical Laboratory, a leading and established lab backed by a decade of experience in providing a comprehensive range of testing solutions, today announced a complete rebranding to become "Gnosis."
  • For 10 years, Mountain View Medical Laboratory (MVML) has been a trusted provider of clinical lab services in Riverside County, California.
  • Gnosis is proud to offer the same great care Mountain View Medical Laboratory always has, now with expanded services and more innovative expertise.
  • Safedin "Sajo" Beqaj, Ph.D., HCLD, CC(ABB), Medical Laboratory Director - Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director.

More Than 90 Maltreated Dogs and Puppies Seized from Self-Described Animal Rescue Group in New Jersey

Retrieved on: 
Wednesday, February 21, 2024
Professional, Prosecutor, Ammonia, Assistant, Animal, Injury, Dog, Investigation, Feces, Safety, Society, Nail, ASPCA, Death, Complaint, Urine, Failure

VERNON TOWNSHIP, N.J., Feb. 21, 2024 /PRNewswire/ -- On Feb. 20, 2024, at the request of the Sussex County Prosecutor's Office and the Vernon Township Police Department, the ASPCA® (The American Society for the Prevention of Cruelty to Animals®) assisted in the removal of more than 90 maltreated dogs from the property of a self-described animal rescue group in Vernon Township, N.J. The animals, including young puppies, were seized by law enforcement after they were found living in filthy conditions among their own feces and urine and exposed to high levels of ammonia. Some of the animals had dirty, severely matted coats, including one dog who was found with nails matted into their fur. Some dogs were also underweight and had untreated medical conditions including eye infections and injuries. Several dogs were living in cars, and deceased dogs were also found on the property.

Key Points: 
  • Some of the animals had dirty, severely matted coats, including one dog who was found with nails matted into their fur.
  • Some dogs were also underweight and had untreated medical conditions including eye infections and injuries.
  • Several dogs were living in cars, and deceased dogs were also found on the property.
  • Animal cruelty charges are pending based on evidence collected by the ASPCA and the Sussex County Prosecutor's Office.

nRichDX to Debut New Products & Present Latest Research at AACR 2024 Annual Meeting this April

Retrieved on: 
Tuesday, February 20, 2024
SAN, Urine, OraSure Technologies, Revolution, CFRNA, Liquid biopsy, AACR, Annual general meeting, Nucleic acid thermodynamics, VAF, Agilent Technologies, Plasma, Diagnosis, San Diego Convention Center, Chinese, Prostate cancer

SAN DIEGO, Feb. 20, 2024 /PRNewswire/ -- nRichDX®, best known for the development of its Revolution Sample Prep System™, will be introducing new products, presenting new data, and exhibiting at the American Association for Cancer Research (AACR) 2024 Annual Meeting. Held April 5-10 at the San Diego Convention Center, the conference is dedicated to exploring and recognizing the latest discoveries in cancer research. nRichDX will exhibit in booth #3721, just inside the main registration entrance, and co-present three posters on April 8 & 9. Exhibits open at 1 PM on Sunday April 7 and close at 12:30 PM on Wednesday April 10.

Key Points: 
  • nRichDX will exhibit in booth #3721 , just inside the main registration entrance, and co-present three posters on April 8 & 9.
  • "nRichDX is proud to introduce the next generation of Revolution Sample Prep Instruments and Kits at this year's AACR Annual Meeting."
  • To meet with nRichDX people at AACR 2024 or schedule an in-booth demo, attendees are encouraged to schedule an appointment .
  • To find the latest information about nRichDX's schedule at AACR 2024, please visit nrichdx.com/aacr2024 .